The Annals of Pharmacotherapy. 2008;42(6):806-816. Patients were randomized to receive either ceftobiprole 500mg intravenously over 60 minutes every 12 hours or vancomycin 1 g intravenously over ...

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.

Purpose. The pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of ceftobiprole are reviewed. Conclusion. Ceftobiprole is a ...

Basilea Pharmaceutica will finally be able to bring its antibiotic ceftobiprole to the US market, around 15 years after the drug was first turned down by the FDA. The US regulator has cleared the ...

For Cresemba, this comprises a milestone payment for sales in Canada, by AVIR Pharma Inc, as well as the first sales milestone payment for the Middle East and North Africa (MENA) region, by Hikma ...